Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients

NCT07302464 | Completed

• 1 other identifier: FMASU MS 603/2024
• Study Type: observational
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The work aimed to compare the effects of Sodium-glucose co-transporter-2 (SGLT2) inhibitors on glomerular filtration rate (GFR) in patients with diabetic chronic kidney disease (CKD) and non-diabetic CKD.

Conditions

Diabetes; Sodium Glucose Co-Transporter 2 Inhibitors; Estimated Glomerular Filtration Rate; Chronic Kidney Disease

Outcome Measures

Primary Outcomes (1)

• Change in the estimated glomerular filtration rate

  Change in the estimated glomerular filtration rate (eGFR) was recorded.

  6 months post-procedure

Study Arms (2)

Study group

Chronic kidney disease (CKD) participants with type 2 diabetes mellitus (T2DM)

Other: Sodium Glucose Co-Transporter 2 Inhibitors

Control group

Chronic kidney disease (CKD) participants without diabetes mellitus

Other: Sodium Glucose Co-Transporter 2 Inhibitors

Interventions

Sodium Glucose Co-Transporter 2 Inhibitors OTHER

All candidates start therapy with sodium glucose co-transporter 2 (SGLT2) inhibitors with a dose of 10mg daily Dapagliflozin for 6 months

Control group; Study group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

This case-control study was done on 60 adult chronic kidney disease (CKD) individuals with stage 3 and 4 (eGFR\>\_20ml/min/1.73 m2) according to KIDGO classification at Ain Shams University Hospitals, Cairo, Egypt.

You may qualify if:

• Age ≥ 18 years.
• Both sexes.
• Chronic kidney disease (CKD) participants with stages 3 and 4.

You may not qualify if:

• Patients with type 1 diabetes mellitus (DM).
• Patients with decompensated Chronic liver disease.
• Patients with uncontrolled hypertension.
• Patients with blood pressure (BP) \> 110/70.
• Patients already on the same medication (Sodium Glucose Co-Transporter 2 Inhibitors).
• Patients with a history of recurrent or recent urinary tract infection (UTI).
• Patients with glycated hemoglobin (HbA1c) ≤10.
• Adult polycystic kidney disease.
• All patients on immunosuppressive medications.

Sponsors & Collaborators

• Ain Shams University: lead

Study Sites (1)

Ain Shams University

Cairo, 11591, Egypt

Location

MeSH Terms

Conditions

Diabetes Mellitus; Renal Insufficiency, Chronic

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor of Internal Medicine and Nephrology, Faculty of Medicine, Ain shams University, Cairo, Egypt

Study Record Dates

• First Submitted: December 11, 2025
• First Posted: December 24, 2025
• Study Start: October 1, 2024
• Primary Completion: June 1, 2025
• Study Completion: June 1, 2025
• Last Updated: December 24, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)